This is supported by a recent study by Pedersen et al. who showed that therapeutic drug monitoring of TNF inhibitors leads to better clinical response and cost management in the treatment of patients with rheumatic diseases [52]. The gene discussed is TNF; the disease is rheumatic disorder.